A Phase I Dose-Escalation Study of IMAB362 (Zolbetuximab) in Patients With Advanced Gastric and Gastro-Oesophageal Junction Cancer

European Journal of Cancer - United Kingdom
doi 10.1016/j.ejca.2018.05.007
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Systematic Review of Health-State Utility Values in Advanced Gastric, Oesophageal, or Gastro-Oesophageal Junction Adenocarcinoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2011English

Phase I Dose-Escalation Study of Copanlisib in Combination With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Multidisciplinary Management of Stage II-III Gastric and Gastro-Oesophageal Junction Cancer

European Journal of Cancer
Cancer ResearchOncology
2020English

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2016English

Phase I Dose‐escalation Study of Volasertib in Pediatric Patients With Acute Leukemia or Advanced Solid Tumors

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2019English

A Phase I Dose-Escalation Study of Selumetinib in Combination With Docetaxel or Dacarbazine in Patients With Advanced Solid Tumors

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

A Phase I Dose-Escalation Study of a Biosimilar Trastuzumab in Chinese Metastasis Breast Cancer Patients

SpringerPlus
Multidisciplinary
2015English

Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination With Bevacizumab in Patients With Advanced Solid Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy